Seattle, USA-based hematology company CTI BioPharma (Nasdaq: CTIC) has won approval from the US Food and Drug Administration for Vonjo (pacritinib) in myelofibrosis.
The rare blood cancer, which affects about 21,000 people in the country, causes scarring of the bone marrow, making it difficult for the body to produce blood cells.
Vonjo is approved for the treatment of certain adults with intermediate or high-risk primary or secondary forms of the disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze